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resumo 
 
 
As doenças da β-oxidação mitocondrial dos ácidos gordos fazem parte do 
painel de doenças detetadas no rastreio neonatal na grande maioria dos 
países desenvolvidos, incluindo Portugal. A deficiência múltipla das acil-CoA 
desidrogenases é uma das doenças rastreadas, sendo rara e apresentando 
um padrão de transmissão autossómico recessivo. Esta disfunção no 
metabolismo dos ácidos gordos é caracterizada por fenótipos bastante 
distintos, sendo reconhecidas duas formas clínicas: moderada e grave. 
Estudos anteriores do nosso grupo de investigação revelaram que o 
proteoma mitocondrial de pacientes homozigotos para a mesma mutação 
evidencia níveis de expressão diferentes das mesmas proteínas e que os 
pacientes com formas moderadas da doença apresentam semelhanças e 
diferenças quando comparados com pacientes com formas graves. O 
objetivo deste estudo foi relacionar as alterações dos processos biológicos 
associados à homeostasia mitocondrial com a severidade da doença, 
associada a mutações no gene que codifica a proteína electron transfer 
flavoprotein dehydrogenase (ETFDH), traçando semelhanças e diferenças. 
No geral, o nosso estudo fornece uma perspetiva global da dinâmica 
mitocondrial nas duas formas da doença. Ambas as formas, moderada e 
grave, apresentaram biogénese mitocondrial diminuída e adaptação 
metabólica, suportadas por níveis baixos de peroxisome proliferator-
activated receptor γ coactivator 1 alpha (PGC-1α) e de gliceraldeído-3-
fosfato desidrogenase (GAPDH), respetivamente, em todos os pacientes 
com a doença. Os níveis de expressão de sirtuina 3 (SIRT3) e a atividade de 
ATP sintase foram encontrados diminuídos em quase todos os pacientes, 
sugerindo uma disfunção mitocondrial. Os níveis reduzidos de SIRT3 foram 
corroborados pela diminuição dos níveis de PGC-1α. Os níveis de expressão 
das outras proteínas analisadas foram diversos entre os pacientes e, 
portanto, sugerem que a correlação entre a severidade da doença e as 
adaptações mitocondriais não é transversal a todas as formas da doença. 
De facto, os diferentes resultados obtidos podem explicar, pelo menos em 
parte, a variedade de fenótipos observados em pacientes com a doença. 
Neste sentido, são necessários mais estudos para compreender melhor a 
patogénese da doença. No futuro, seria interessante analisar os efeitos da 
deficiência de ETFDH noutras células em vez de fibroblastos e pesquisar 
outros metabolitos energéticos relacionados com estes mecanismos. 
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abstract 
 
Mitochondrial fatty acid β-oxidation disorders are some of the many diseases 
detected by newborn screening in most developed countries, including 
Portugal. Among screened disorders, multiple acyl-CoA dehydrogenase 
deficiency (MADD) is a rare autosomal recessively inherited disorder that 
presents very distinct phenotypes, being recognized in two clinical forms: 
mild and severe. Previous studies from our research group showed that the 
mitochondrial proteome of homozygous patients having the same mutation 
presents different expression levels of the same proteins and that patients 
with mild forms of MADD share some proteins with severe forms and at the 
same time present distinctive expression patterns. The aim of this study was 
to relate the regulation of biological processes associated to mitochondrial 
homeostasis with the severity of MADD, due to mutations on the gene that 
codifies the protein electron transfer flavoprotein dehydrogenase (ETFDH), 
evidencing similarities and differences. 
In overall our study provides a global perspective of the mitochondrial 
dynamics in the two forms of MADD, mild and severe. Both forms presented 
down-regulation of mitochondrial biogenesis and metabolic adaptation 
highlighted by lower levels of peroxisome proliferator-activated receptor γ 
coactivator 1 alpha (PGC-1α) and glyceraldehyde-3-phosphate 
dehydrogenase (GAPDH), respectively, in all MADD patients. Expression 
levels of sirtuin 3 (SIRT3) and the activity of ATP synthase were found 
decreased in almost all patients, suggesting mitochondrial dysfunction. 
Down-regulation of SIRT3 was corroborated by decreased levels of PGC-1α. 
The expression levels of the other proteins analyzed were diverse among 
MADD patients and thus highlighting no straight full correlation between 
disease severity and mitochondrial adaptations. In fact, the different results 
obtained may explain, at least in part, the variety of phenotypes observed in 
MADD patients. So, more studies are needed to better understand MADD 
pathogenesis. In the future, it would be interesting to analyze the effects of 
ETFDH deficiency in other cell types rather than fibroblasts and search for 
other energetic metabolites related with these mechanisms. 
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Fatty acid oxidation defects are a group of inherited metabolic disorders, affecting the 
enzymes involved in the oxidation of fatty acids (1,2). These disorders are usually 
transmitted in an autosomal recessive pattern being individually rare, but together they 
represent a large and important group of inherited metabolic disorders (1). Patients have 
heterogeneous clinical phenotypes and the same metabolic blockage may be associated to 
very different clinical phenotypes. The main affected organs include heart, liver and 
skeletal muscles (2). The mortality and morbidity rates associated with these conditions 
can be prevented, or at least decreased, if disorders are early recognized and treated (1). 
Indeed, fatty acid oxidation disorders can lead to serious health problems and even to death 
if not treated or when the diagnosis is done too late. The advantages of an early 
intervention make this group of disorders main targets of newborn screening (NBS) 
programs worldwide (1,3,4). The NBS aims to identify newborns with serious but treatable 
health diseases before the onset of symptoms and the development of irreversible damage 
(5,6). Since the introduction of tandem mass spectrometry (MS/MS) into screening 
programs in the 1990s, the number of inherited metabolic disorders screened greatly 
increased, including amino acid, organic acid and fatty acid metabolism disorders, since 
this technique allows the simultaneously determination of many analytes on the same 
analysis (1,5). NBS is one of the most successful public health programs initiated in the 
last fifty years (1,6). 
Among mitochondrial fatty acid β-oxidation (FAO) disorders, multiple acyl-CoA 
dehydrogenase deficiency (MADD) is one of the twenty-five disorders screened by NBS in 
Portugal. The birth prevalence of MADD is 1:164,765 in Portugal (7). These FAO 
disorders (FAOD) result from defects in enzymes of mitochondrial fatty acid β-oxidation; 
however, in most cases the association between the phenotype and the genotype is not 
straightforward (2,8), which suggest that other individual cellular/molecular mechanisms 
might interfere with disease pathogenesis. Herein, we overview FAO metabolism, its 
regulation and contextualize MADD, the chosen model to study mitochondrial dynamics 
disturbances in FAO. We also critically analyze the potential contribution of the molecular 
pathways harbored in mitochondria or involved in the regulation of its functionality to the 
pathogenesis of FAOD, giving emphasis to MADD. 
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1.1. Mitochondrial fatty acid β-oxidation 
The main function of mitochondrial fatty acid β-oxidation (FAO) is to generate acetyl-
coenzyme A (acetyl-CoA) and reducing equivalents such as flavin adenine dinucleotide 
(FADH2) and nicotinamide adenine dinucleotide (NADH), especially during periods of 
fasting and metabolic stress. These molecules are linked to the Krebs cycle and to the 
oxidative phosphorylation (OXPHOS) system leading to energy production in the form of 
adenosine triphosphate (ATP) (9,10). Figure 1 overviews the FAO pathway from the 
activation of fatty acids to the generation of acetyl-CoA and its association with the Krebs 
cycle and OXPHOS. 
OXPHOS is the key metabolic pathway in mitochondrial energy production. It requires the 
action of five multiheteromeric complexes located in the inner mitochondrial membrane, 
designated complexes I to V (11,12). Electrons donated from NADH are passed from 
complex I to complex III through ubiquinone (CoQ). In addition, CoQ also takes electrons 
from succinate via complex II and from electron transfer flavoprotein-ubiquinone 
oxidoreductase (ETF-QO). Finally, cytochrome c (Cyt c), an iron-containing heme protein, 
shuttles electrons from complex III to IV, which transfers its electrons to oxygen (O2), the 
final electron acceptor. During this process, the electrochemical gradient generated by the 
pumping of protons out of the mitochondrial inner membrane to the intermembrane space, 
is used by complex V in order to convert adenosine diphosphate (ADP) to ATP (12) 
(Figure 1). 
Adipose tissue triacylglycerides (TG) are the primary source of fatty acids (FA) used for 
FAO. During fasting conditions TG are mobilized, transported and distributed to various 
tissues through bloodstream in lipoproteins (9). Once inside the cells, long-chain FA 
(LCFA) are activated to their coenzyme A (CoASH) esters and transported into 
mitochondria for subsequent β-oxidation (9,10,13). The transporter involved in the process 
corresponds to the “carnitine shuttle” that requires the concerted action of three proteins: 
carnitine palmitoyltransferase 1 (CPT1), carnitine/acylcarnitine translocase (CACT), and 
carnitine palmitoyltransferase 2 (CPT2). CPT1 converts acyl-CoA compounds to their 
acylcarnitine metabolites at the outer mitochondrial membrane. CACT transports the 
acylcarnitines across the inner mitochondrial membrane in exchange for free carnitine, and 
CPT2 re-esterifies the acylcarnitines to their acyl-CoA esters on the inner mitochondrial 
membrane (13). In contrast, the short-chain and medium-chain FA (SCFA and MCFA) 
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diffuse freely across the mitochondrial membrane into the matrix, where they are activated 
to their corresponding acyl-CoA esters, which are oxidized by FAO enzymes (9,10,14). 
Once in the mitochondrial matrix FA are oxidized by the -oxidation system (Figure 1). 
 
 
Figure 1. Schematic representation of mitochondrial fatty acid β-oxidation and its association with Krebs 
cycle and OXPHOS. Figure made with Servier Medical Art. Abbreviations: ACAD: acyl-CoA 
dehydrogenases, acetyl-CoA: acetyl-coenzyme A, ACS: acyl-CoA synthetase, ADP: adenosine diphosphate, 
ATP: adenosine triphosphate, C-I: nicotinamide adenine dinucleotide-ubiquinone oxidoreductase, C-II: 
succinate dehydrogenase, C-III: ubiquinol-cytochrome c reductase, C-IV: cytochrome c oxidase, C-V: ATP 
synthase, CACT: carnitine/acylcarnitine translocase, CoASH: coenzyme A, CoQ: ubiquinone, CPT1: 
carnitine palmitoyltransferase 1, CPT2: carnitine palmitoyltransferase 2, Cyt c: cytochrome c, e-: electrons, 
ECH: 2-enoyl-CoA hydratases, ETF: electron transfer flavoprotein, ETFDH: electron transfer flavoprotein 
dehydrogenase, FAD: flavin adenine dinucleotide, FADH2: reduced form of FAD, HAD: 3-hydroxyacyl-CoA 
dehydrogenases, H2O: water, KAT: 3-ketoacyl-CoA thiolases, LACS: long-chain acyl-CoA synthetase, LC-
carnitine: long-chain fatty acylcarnitine ester, LC-CoA: long-chain fatty acyl-CoA ester, LCFA: long-chain 
fatty acids, MC-CoA: medium-chain fatty acyl-CoA ester, MCFA: medium-chain fatty acids, MTP: 
mitochondrial trifunctional protein, NAD+: nicotinamide adenine dinucleotide, NADH: reduced form of 
NAD+, O2: oxygen, OH: hydroxy, OXPHOS: oxidative phosphorylation, Pi: inorganic phosphate, SC-CoA: 
short-chain fatty acyl-CoA ester, SCFA: short-chain fatty acids, VLCAD: very long-chain acyl-CoA 
dehydrogenase. 
  
6 
The β-oxidation cycle is characterized by four sequential steps in which an acyl-CoA ester 
undergoes dehydrogenation, hydration, dehydrogenation again and finally thiolytic 
cleavage (Figure 1). These steps are catalyzed by enzymes with overlapping chain length 
specificities (10,14). Beta-oxidation can also occur in peroxisomes, although it is different 
from mitochondrial oxidation in terms of enzymology, regulation, energy production and 
especially substrate specificity (15,16). Indeed, LCFA are mainly oxidized in peroxisomes 
and after shortening of their chain length, they are transported to mitochondria (15). Inside 
mitochondria, FA are metabolized by FAO enzymes and fully oxidized to carbon dioxide 
(CO2) and water (H2O) by Krebs cycle and OXPHOS, respectively (14). There are another 
types of FA oxidation such as α- and ω-oxidation, which require additional enzymes for 
the oxidation of branched-chain or odd-numbered FA (14,17). 
The first step in β-oxidation cycle is catalyzed by at least three distinct acyl-CoA 
dehydrogenases (ACAD), each having preference for acyl-CoA substrates of differing 
chain lengths: very long-chain acyl-CoA dehydrogenase (VLCAD) acts on C12-C24 
substrates, medium-chain acyl-CoA dehydrogenase (MCAD) acts on C6-C16 substrates, 
and short-chain acyl-CoA dehydrogenase (SCAD) acts on C4-C6 substrates (14,18). There 
are other two additional ACAD with less well established physiological roles: long-chain 
acyl-CoA dehydrogenase (LCAD) and acyl-CoA dehydrogenase 9 (19). SCAD, MCAD 
and LCAD are soluble, mitochondrial matrix enzymes composed of four identical subunits 
with a native molecular mass of 160-180 kDa, whereas VLCAD is membrane-bound and is 
not a tetramer but a dimer of two identical subunits of about 70 kDa. Each of these 
subunits carries a flavin adenine dinucleotide (FAD) noncovalently bound at the active 
site, supporting the activity of these enzymes in the catalysis of a FAD-linked 
dehydrogenation (18). Reoxidation of the reduced flavoproteins is possible by electron 
transfer flavoprotein (ETF), which has FAD as prosthetic group, and passes reducing 
equivalents to another flavoprotein called electron transfer flavoprotein-ubiquinone 
oxidoreductase (ETF-QO) (18,20). ETF-QO, also designated as electron transfer 
flavoprotein dehydrogenase (ETFDH), passes its electrons to the mitochondrial electron 
transport chain via CoQ (Figure 1). ETF is a dimer of two nonidentical subunits, α and β, 
containing one FAD molecule and is localized in the mitochondrial matrix, while ETFDH 
is a flavoprotein localized in the inner mitochondrial membrane with 68 kDa (9,20). 
Crystallographic studies support the association ACAD-ETF-ETFDH during electron and 
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hydrogen transfer from ETFDH to CoQ, which delivers electrons to complex III of 
OXPHOS (20) (Figure 1). 
The second step of β-oxidation is the hydration of 2-trans-enoyl-CoAs to their 
corresponding 3-hydroxyacyl-CoAs catalyzed by 2-enoyl-CoA hydratases (ECH) (Figure 
1). There are at least two distinct enzymes: crotonase and long-chain 2-enoyl-CoA 
hydratase (LCECH). The first, composed of six identical subunits, is most active for short-
chain substrates, while the second, responsible for hydration of long-chain substrates, is 
part of the mitochondrial trifunctional protein (MTP) (10,14). 
The third step of the β-oxidation cycle involves the dehydrogenation of 3-hydroxyacyl-
CoAs to 3-oxoacyl-CoAs by two distinct forms of 3-hydroxyacyl-CoA dehydrogenases 
(HAD) (Figure 1). Short- and medium-chain substrates are preferentially dehydrogenated 
by a generic short- to medium-chain hydroxyacyl-CoA dehydrogenase, which was first 
described as short-chain 3-hydroxyacyl-CoA dehydrogenase (SCHAD), a dimer of two 
identical subunits of 33 kDa each. Long-chain 3-hydroxyacyl-CoA dehydrogenase 
(LCHAD) is the other specific enzyme and belongs to the MTP (9,14). 
In the last step of β-oxidation, 3-ketoacyl-CoAs are converted to acetyl-CoA and its 
corresponding acyl-CoA ester two-carbon atoms shorter by thiolytic cleavage (9,10) 
(Figure 1). This reaction is catalyzed by thiolases, which exist in three different isoforms. 
One thiolase, a homotetramer of 42 kDa subunits localized in the mitochondrial matrix, is 
specific for acetoacetyl-CoA and 2-methylacetoacetyl-CoA. The other thiolase, often 
called general thiolase or medium-chain 3-ketoacyl-CoA thiolase (MCKAT), acts on 
substrates ranging from C4 to C12. The third thiolase is the long-chain specific thiolase and 
is one of three proteins of the MTP. MTP is a heterooctamer with four α- and four β-
subunits. The α-subunit carries the enzymes of the second and third steps of β-oxidation 
cycle (LCECH and LCHAD), whereas the β-subunit harbors the thiolase component 
(9,10,14). 
In overall, there are at least twenty-five enzymes and specific transport proteins involved in 
FAO and defects in many of them are associated with human diseases (2,4,21,22). 
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1.2. Disorders of mitochondrial fatty acid β-oxidation 
Several diseases related to defects in β-oxidation enzymes have been identified, which are 
generally designated as mitochondrial fatty acid β-oxidation disorders (FAOD) (2,23). 
FAOD are generally inherited in an autosomal recessive pattern and are individually rare, 
although they are collectively common (1,2). The inherited metabolic defects can be 
assigned to two groups: (a) those associated with the “carnitine shuttle”, for example 
CPT1; and (b) those of β-oxidation spiral, such as SCAD, ETF and ETFDH (23). In table 1 
are represented FAOD from the two distinct groups mentioned above, their protein, gene 
and locus defect, the main acylcarnitines found in plasma and the year which they were 
first described. 
Most FAOD are identified by the acylcarnitine profile analyzed by flow injection 
electrospray ionization (ESI) tandem mass spectrometry (MS/MS) (3,24). In fact, the 
acylcarnitine profile data obtained from NBS programs is crucial for the diagnosis of 
FAOD and consequently to estimate its birth prevalence (4). The birth prevalence is a more 
robust evidence of FAOD since there are significant cases of patients that only present 
symptoms in late infancy or adulthood. In Portugal, the overall birth prevalence of FAOD 
is 1:5,991 live births (7). The acylcarnitine profile found in patients with CPT1 and 
CPT2/CACT deficiencies is very distinct from those observed for ETF and ETFDH 
deficiencies (Table 1). The CPT1 deficiency is associated with elevated levels of free 
carnitine (C0) in plasma and absence of long-chain acylcarnitines due to its inability to 
produce these metabolites (2). In opposite, patients with CPT2/CACT deficiencies present 
elevated levels of long-chain acylcarnitines (C16, C16:1, C18, C18:1) since they are formed but 
are not correctly transported through the mitochondrial membrane. Deficiencies in ETF 
and ETFDH proteins are associated with a varied acylcarnitine profile, ranging from short-
chain (C4) to long-chain (C14, C16) acylcarnitines, since they compromise the function of 
the different chain-specific acyl-CoA dehydrogenases (1,23). However, when the defect is 
in a specific acyl-CoA dehydrogenase (SCAD or VLCAD deficiency) the acylcarnitine 
profile observed is representative of its chain specific substrates (Table 1).  
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Table 1. Genetic and biochemical characteristics of the mitochondrial fatty acid β-oxidation disorders. Gene, 
locus and year information was collected from Sim et al. (23) and Gregersen et al. (28) while the information 
for acylcarnitine profiles was adapted from Sahai et al. (1) and Sim et al. (23). Acylcarnitine profile was 
further completed with information from Olsen et al. (8). 
Deficiency Protein Gene Locus Acylcarnitine 
profiles 
Yeara 
Carnitine shuttle      
Carnitine/acylcarnitine translocase CACT SLC25A2 3p21 
C16, C16:1, 
C18, C18:1 
1992 
Carnitine palmitoyltransferase 1 (liver) CPT1A CPT1A 11q13 C0 1981 
Carnitine palmitoyltransferase 2 CPT2 CPT2 1p32 
C16, C16:1, 
C18, C18:1 
1973 
β-oxidation spiral      
Electron transfer flavoprotein-α ETFα ETFA 15q23 C4, C5, C5DC, 
C6, C8, C10, 
C12, C14; 
C5-OH, C14:1, 
C16, C16:1 
1986 
Electron transfer flavoprotein-β ETFβ ETFB 19q13 1991 
Electron transfer flavoprotein 
dehydrogenase 
ETFDH ETFDH 4q32 1985 
Long-chain 3-hydoxyacyl-CoA 
dehydrogenase (isolated) 
LCHAD HADHA 2p23 
C14-OH, C16-OH, 
C18-OH, C18:1-OH 
1988 
Long-chain 3-ketoacyl-CoA thiolase LCKAT HADHB 2p23 
C16-OH, C18-OH, 
C18:1-OH 
1996 
Medium-chain acyl-CoA dehydrogenase  MCAD MCAD 1p31 
C6, C8, C10, 
C10:1 
1982 
Medium-chain 3-ketoacyl-CoA thiolase MCKAT ACAA2 NR C4 to C8 1997 
Medium/Short-chain 3-hydroxyacyl-CoA 
dehydrogenase 
M/SCHAD HADHSC 4q22-26 
C4-OH, C6-OH, 
C8-OH 
1996 
Mitochondrial trifunctional protein-α 
LCECH 
LCHAD 
HADHA 2p23 
2p23 
C16-OH, C18-OH, 
C18:1-OH 
1992 
Mitochondrial trifunctional protein-β LCKAT HADHB 
Short-chain acyl-CoA dehydrogenase SCAD ACADS 12q22 C4 1984 
Very long-chain acyl-CoA 
dehydrogenase 
VLCAD ACADVL 17p11 
C14, C14:1, 
C14:2, C16, C18:1 
1993 
a: Year of the first defect described. Abbreviations: C5DC: glutarylcarnitine, Cnumber: acylcarnitine species with 
the corresponding carbon chain length, Cnumber-OH: 3-hydroxyacylcarnitine species with the corresponding 
carbon chain length, NR: not reported. 
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The symptoms of FAOD are diverse according to the type of defective enzyme being 
associated with reduced production of energy-yielding substrates (acetyl-CoA and ketone 
bodies) and accumulation of free fatty acids and toxic acyl-CoA intermediates and their 
respective acylcarnitines and acylglycines in tissues (2,22,25). The main organs affected 
are skeletal muscle, heart and liver since they are highly reliable on FAO to obtain energy. 
Consequently, the principal symptoms include fasting hypoglycemia, rhabdomyolysis, 
cardiomyopathy or hepatic dysfunction (2,22). However, hypoketotic hypoglycemia is the 
hallmark, being present in almost all disorders due to shortage of acetyl-CoA and ATP 
which lead to sustain glucose and ketone bodies formation (2,21,22,25). In general, acute 
symptoms are precipitated by infections, fasting, prolonged exercise and stress because 
these conditions require energy from FAO metabolism resulting in increased levels of 
accumulated metabolites (2,25). 
Some FAOD, including CPT2 deficiency, VLCAD deficiency (VLCADD) and multiple 
acyl-CoA dehydrogenase deficiency (MADD), have showed a certain degree of correlation 
between genotype and phenotype, whereas for MCAD deficiency (MCADD), which is the 
most incident FAOD in Portugal with a birth prevalence of 1:7,973 (7), the phenotype-
phenotype correlation is poor (26–28). In fact, the clinical heterogeneous phenotypes 
observed in FAOD result from the interaction among the genetic mutations, their 
interactions with other genes and with environmental factors. Consequently, understand the 
molecular mechanisms underlying these interactions is crucial to better elucidate the 
pathophysiology of FAOD (27,28).  
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1.2.1. Multiple acyl-CoA dehydrogenase deficiency 
Multiple acyl-CoA dehydrogenase deficiency (MADD) is a rare disorder of fatty acid, 
amino acid and choline metabolism inherited in an autosomal recessive pattern (29,30). 
The clinical signs observed are due to defects in electron transfer flavoprotein (ETF) or 
electron transfer flavoprotein dehydrogenase (ETFDH) proteins, which leads to secondary 
defects of FAD-dependent enzymes such as acyl-CoA dehydrogenases (29,31). These two 
proteins, ETF and ETFDH, are essential factors for the flavoproteins to deliver electrons to 
ubiquinone (CoQ) and therefore they make the interplay between β-oxidation and 
OXPHOS. The recommended long-term treatment of MADD includes riboflavin, carnitine 
or glycine, and a diet restricted in fat and protein and high in carbohydrate. In addition to 
these, fasting avoidance is also recommended (32,33). 
In Portugal, the prevalence of MADD is 1:164,765 according to the report of the 
Portuguese Newborn Screening Program (7). MADD was firstly described in 1976 by 
Przyrembel and co-workers (34). The main findings retrieved from patient’s analysis were 
the excretion of glutarate, isovalerate, severe untreatable hypoglycemia, elevation of long-
chain fatty acids in serum and fatty infiltration of the liver. These evidences do not 
correlate to those described in the cases of glutaric aciduria type I (GA I) (35,36); however, 
as the main biochemical abnormality was the excess of glutaric acid, the authors proposed 
the designation of glutaric aciduria type II (GA II). This denomination distinguishes it from 
GA I, which is due to isolated glutaryl-CoA dehydrogenase deficiency (35,36). Actually 
the term MADD is more used because it describes more precisely the metabolic deficiency, 
although GAII is still used (37). 
MADD is generally characterized by hypoketotic hypoglycemia and by accumulation and 
excretion of abnormal amounts of organic acids derived from the substrates of acyl-CoA 
dehydrogenases (1,23,29). In addition to the acylcarnitine profile reported by Sahai et 
al.(1) and Sim et al. (23), MADD is also characterized by elevated concentrations of C16, 
C16:1, C14:1, C5-OH, and ethylmalonic acid (EMA) (8) (Table 1). This acylcarnitine pattern, 
ranging from short- to long-chain, support that almost all acyl-CoA dehydrogenases are 
malfunctional. ETF is a dimer of two nonidentical subunits, α and β, derived from ETFA 
(locus 15q23) and ETFB (locus 19q13) genes, respectively. ETFDH is codified by locus 
4q32 from ETFDH gene (23) (Table 1). Thus, mutations on ETFA, ETFB and ETFDH 
genes decrease the in vivo activity for all the acyl-CoA dehydrogenases. Indeed, the 
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ETF/ETFDH complex is essential for the acyl-CoA dehydrogenases functionality since it 
accept electrons and protons and transfer them to CoQ (31,37,38). The polymorphism α-
T171, which is responsible for a significant decrease of thermal stability in the ETFA gene 
was reported as significantly overrepresented in VLCADD patients with mild childhood 
presentation (38). Therefore, the residual levels of VLCAD enzyme activity observed in 
these patients support the importance of the ETF/ETFDH proteins in FAO metabolism and 
consequently gives evidence of protein-protein interactions as a possible mechanism 
underlying the pathophysiology of FAOD. 
 
 
1.2.1.1. Relation between genotype and phenotype in MADD 
Patients with MADD have been classified in three distinct clinical forms (22,33,39). In the 
neonatal-onset form (type I), the patients are often premature and characterized by 
dysmorphic features including high forehead, hypoplastic midface, wide-open anterior 
fontanel, abnormal genitalia and renal cysts. In addition, they can present hypotonia, 
hepatomegaly, hypoketotic hypoglycemia, metabolic acidosis and excretion of large 
amounts of abnormal fatty acid and organic acid metabolites (22). Generally, most of these 
patients die within the first week of life. In type II, the clinical presentation is most likely 
type I, but without the congenital abnormalities (39). The patients’ phenotype of mild- or 
late-onset forms (type III) is extremely variable, ranging from recurrent episodes of 
lethargy, vomiting, hypoglycemia, metabolic acidosis and hepatomegaly often triggered by 
fever, infection or fasting to progressive lipid storage myopathy in adulthood or even 
asymptomatic cases (22,33,39). 
 
Riboflavin-responsive multiple acyl-CoA dehydrogenase deficiency (RR-MADD) is a 
variant of MAD defects, firstly described in 1982 (40). In the originally studied patient, the 
urine organic acid and plasma acylcarnitine profile were abnormal and similar to those 
with other forms of multiple acyl-CoA dehydrogenation defects, and normalized after 
riboflavin treatment (40). Riboflavin is the precursor of FAD, which is a cofactor for many 
enzymes such as acyl-CoA dehydrogenases, ETFDH and other mitochondrial enzymes, 
acting as a chaperone too, being essential for the folding and stability of these 
flavoproteins (8,41). All the patients with RR-MADD studied by Olsen and co-workers 
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(42) harbored pathogenic variations in the ETFDH gene. These variations may affect the 
biogenesis, stability and activity of the ETFDH protein (42). Indeed, patients with RR-
MADD showed milder folding defects of ETFDH variants, with a significant increase in 
protein stability and activity after riboflavin treatment (43). It is not clear whether lack of 
ETFDH or aberrant accumulated ETFDH protein affects FAD functionality or its 
precursors (42,44). When mutations in ETFDH, ETFA or ETFB genes are not present, the 
possibility of defects on riboflavin transporters should be investigated. In fact, these 
defects lead to cellular riboflavin deficiency, which biochemical and clinical abnormalities 
may mimic MADD and is possible that some patients with genetic riboflavin transporter 
defects have been misdiagnosed with MADD (33,41,45). Since the pathogenic variations 
are generated by single nucleotide substitutions and localized near the CoQ or FAD 
binding domains, patients suspected of RR-MAD should be treated with both riboflavin 
and CoQ (37). 
 
For the three clinical types of MADD it has been described a certain degree of correlation 
between genotype and phenotype (26,46). Indeed, nonsense, frameshift and splice junction 
mutations that may lead to messenger ribonucleic acid (mRNA) degradation by the 
nonsense-mediated mRNA decay (NMD) system or by other processes result in complete 
absence of functional protein are associated with severe, in many cases fatal, clinical 
disease (severe MADD). On opposition, missense mutations and small in-frame deletions 
and insertions are usually associated with milder clinical presentations (mild MADD) 
(37,47). Commonly, homozygosity for null ETF or ETFDH mutations is associated with 
the type I/II (26,39). The late-onset patients carry at least one missense variation, 
especially in ETFDH gene, while ETFA or ETFB mutations are less common in these 
individuals. Interestingly, almost patients with late-onset MADD are clearly responsive to 
riboflavin, since they usually present a ETFDH missense mutation which is more common 
associated with RR-MADD phenotypes (33). In table 2 are presented the number of these 
mutations type for each gene associated with MADD. 
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Table 2. Type and number of gene mutations in MADD. Adapted from Gregersen et al. (47). 
Gene Splice 
changes 
Stop 
codons 
Out-of-frame 
deletion/insertions 
In-frame 
deletion/insertions 
Missense 
variations  
ETFA 1 2 5 1 11 
ETFB 2   1 5 
ETFDH 2 3 6  17 
 
Indeed, a higher number of missense variations has been identified in ETFDH gene 
compared to the other genes (Table 2). According to this, it would be expected milder 
phenotypes related to ETFDH mutations. However, severe forms for this gene have been 
reported (48,49). The genotype-phenotype correlation in MADD is poor due to other 
factors that may modulate the clinical phenotype. Exogenous factors such as febrile 
infections, cellular temperature, a restricted diet and other physiologic stressors, in addition 
of the disease-causing mutation, contribute to heterogeneous phenotypes (26,33). 
 
ETF deficiency, due to changes of one of its subunits, results in substrate blockage, and 
depending on the nature of the causing mutations may lead to the accumulation of 
misfolded, inactive conformations of ETF proteins (26). The mitochondrial functionality is 
consequently disturbed, resulting in energy deficiency, accumulation of hydrogens and 
reducing equivalents, increase in ROS production and oxidative stress (46). When 
monomeric ETFDH is missing or present but defective, the effects are similar to those in 
the ETF deficiency (26). So, deficiencies in both ETF and ETFDH lead to the 
accumulation and excretion of metabolites that reflect functional deficiency of 
ETF/ETFDH-dependent enzymes, damaging and inactivating them, disabling the shuttle of 
reducing equivalents and resulting in increased ROS (37,42). 
Interestingly, the increase of ROS levels, produced directly by electron leakage from 
misfolding variant ETFDH proteins or as result of mitochondrial dysfunction, triggers 
activation of cellular defense signaling pathways to facilitate cellular adaption to mutation 
(50). It was reported that mild misfolding of ETFDH enzymes, with impaired CoQ 
binding, results in increased content of superoxide radical anion (O2
•−), due to the disturbed 
electron transfer pathway from the ETFDH to CoQ. (43). Indeed, several studies associate 
these biochemical alterations with increased oxidative stress (26,42,43,46,48). Therefore, 
the subjacent mechanisms that regulate cell homeostasis and signaling pathways are 
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dysregulated, leading to multi-organ failure and the observed clinical phenotypes (50). 
Thus, the study of the molecular pathways harbored in mitochondria or involved in the 
regulation of its functionally is crucial to understand the pathogenesis of MADD and 
therefore in FAOD, since mitochondrial dysfunction have been related with these disorders 
(27,46,51). 
 
 
 
1.3. The role of mitochondria on the regulation of cell homeostasis in 
FAOD 
Mitochondria are intracellular double membrane-bound structures ubiquitous in eukaryotes 
and essential in the regulation of cellular homeostasis and survival (25,52,53). Their 
primary function is to provide energy substrates being considered the powerhouses of the 
cell. Furthermore, they have an important role in the regulation of apoptosis and redox 
homeostasis (50,54,55). Dysregulation of the metabolic pathways harbored in 
mitochondria can lead to mitochondrial disorders, such as FAOD. In parallel to metabolic 
disturbances, broad alterations in mitochondrial functionality have been reported in FAOD 
(8,27,46,50,51). In fact, it is accepted that the accumulated acylcarnitines and their 
derivatives due to defects in FAO enzymes disturb the mitochondrial homoeostasis (25). 
 
Mitochondria are major sources of reactive oxygen species (ROS), which include free 
radicals such as hydroxyl radical (HO•), peroxyl radical (RO2
•) and alkoxyl radical (RO•) 
as well as nonradical species (hydrogen peroxide: H2O2) (8,56). Superoxide radical anion 
(O2
•−), which results from the partial reduction of O2, and thereby ROS are mainly 
generated at complexes I and III of OXPHOS, being a side product of respiration (57,58). 
Other local of ROS production inside mitochondria is the ETF complex, by ETF and 
ETFDH electron leakage (58,59), which is of particular relevance in FAOD (8,59). 
Superoxide radical anion may react with nitric oxide (NO), produced within mitochondria, 
forming the radical peroxynitrite (ONOO•−). These two radicals are designated as reactive 
nitrogen species (RNS) (57). 
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ROS and RNS trigger antioxidant and protein quality control (PQC) systems to regulate 
their intracellular levels and maintain cellular homeostasis (55,60). Inside mitochondria, 
the antioxidant systems involve the action of manganese superoxide dismutase (MnSOD), 
peroxiredoxin (Prx III), thioredoxine (Trx II) and glutathione peroxidase (GPx), and also of 
mitochondrial glutathione (mtGSH). MnSOD converts O2
•− to H2O2, and this molecule can 
be reduced to HO• or be detoxified to H2O by GPx and Prx III (55,57,60). Mitochondrial 
GSH is crucial in mitochondria homeostasis, regulating ROS generation and survival 
pathways. Indeed, decreased levels of mtGSH are associated with loss of mitochondrial 
membrane potential and release of cytochrome c (Cyt c) from mitochondria (61). 
On the other hand, when the ROS and RNS levels exceed the threshold necessary for 
maintaining the healthy state, mitochondria and other cellular components are damaged, 
which triggers cellular dysfunction (57). Indeed, ROS and RNS produced at mitochondria 
oxidize the biomolecules nearby including mitochondrial deoxyribonucleic acid (mtDNA), 
phospholipids and proteins. These molecules are particularly susceptible to oxidative 
damage, and their function can be altered leading to mitochondrial dysfunction and, 
eventually to cell dysfunction and death if the damage is not repaired. Consequently, more 
ROS and RNS are generated and pathological processes may start due to cell dysfunction 
and death, in a vicious cycle (50,55,57,60). FAO-related inherited gene defects result in the 
accumulation of substrates and misfolded proteins and consequently in chronic oxidative 
stress (8). In fact, increased levels of ROS and elevated expression levels of antioxidant 
enzymes, such as MnSOD and peroxiredoxin-6, were reported among FAOD (8,48,62). 
 
When mitochondria are damaged and dysfunctional, mitophagy, mitoptosis and autophagy 
must be activated to eliminate damaged organelles to avoid cellular dysfunction (53,63). 
When these mechanisms are not correctly working or are overwhelmed, cell death 
pathways should be activated (8,52,60). Indeed, mitochondrial damage-induced autophagy 
leads to preferential degradation of impaired mitochondria in a process designated 
mitophagy (52). This process consists on opening of permeability transition pore (PTP) in 
individual mitochondria, leading to depolarization of them, which are sequestered to form 
autophagosomes (64,65). Then, autophagosomes fuse with lysosomes to create 
autolysosomes, where mitochondrial digestion and degradation take place (52,66). So, 
autophagy can be seen as a mitochondrial quality control process, since it prevents 
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proliferation of defective mitochondria (52,63). Indeed, increased mitophagy was reported 
in RR-MADD, evidenced that mitochondria damaged by elevated ROS were eliminated by 
this mechanism in those patients (67). However, more studies focused on the contribution 
of mitophagy to the pathogenesis of FAOD are needed. 
Mitoptosis is a more robust mechanism of mitochondria elimination that also protects cells 
from the damage caused by malfunctioning mitochondria (68,69). This process starts with 
fission of mitochondrial filaments into small spherical structures, leading to fragmentation 
of mitochondria (68). This step has been reported in apoptosis, suggesting that mitoptosis 
may initiate cell death when the damage of mitochondria is irreversible (70). After this, 
clusters of mitochondria are formed in the perinuclear region depending on cytoskeletal 
elements including microtubules, actin microfilaments and intermediate filaments. The 
clusters are occluded by a membrane to form the mitoptotic bodies, where mitochondrial 
decomposition takes place. The final step is protrusion of the mitoptotic bodies from the 
cell, releasing them into the extracellular medium (68,69). The mitoptotic program could 
be induced by several factors such as ATP depletion, block of respiration or depolarization 
of mitochondrial membrane, although overproduction of ROS has been reported as the 
main factor that triggers mitoptosis. ROS seem to induce PTP opening as observed in 
autophagy. Indeed, mitoptosis is not independent of mitophagy since autophagosomes and 
lysosomes are probably involved in the intermediate steps of mitoptotic body formation 
(68). When certain mitochondria become ROS overproducers, mitophagy is the 
preferential mitoptotic mechanism chosen (52,69). However, when ROS overproduction 
occurs in the entire mitochondrial population, mitoptosis looks like a more adequate 
mitoptotic mechanism (68). 
 
When cells cannot be saved by the mitophagy or mitoptosis mechanisms, apoptosis takes 
over (8,52,60). The main mediators of apoptosis are caspases (cysteine-aspartic proteases), 
which are proteolytic enzymes that cleave inactive precursors to their active form (71,72). 
Caspases are a family of enzymes containing more than ten proteins divided into initiator 
(caspase-8 and -9) and executioner (caspase-3 and -7) ones. The initiator caspases, 
activated by cellular specific proteins, cleave executioner caspases which cleave protein 
substrates, being the executors of apoptosis (71). There are two main pathways the 
extrinsic and the intrinsic ones that leads to cell apoptosis (72). A schematic representation 
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of these apoptotic pathways is presented in figure 2, giving special attention of 
mitochondria-induced effectors. 
 
 
Figure 2. Extrinsic and intrinsic apoptotic pathways. The extrinsic pathway is initiated by binding of ligands 
to their respective DR, which leads to the formation of DISC and activates Casp-8 and this directly activates 
Casp-3, executing apoptosis. Casp-8 also activates Bid, starting the intrinsic pathway, which interacts with 
mitochondrial pro-apoptotic proteins Bax and Bak, leading to the release of several pro-apoptotic proteins, 
which triggers caspase-dependent (black arrows) or caspase-independent (blue arrows) cytosolic signaling 
events. Cyt c binds to Apaf-1 to form the apoptosome that recruits and activates Casp-9 which activates 
Casp-3. Caspase activation is improved by Smac/Diablo and Omi/HtrA2 since they inhibit IAPs. AIF and 
EndoG bind with DNA, inducing DNA fragmentation, via caspase-independent pathway. The intrinsic 
apoptotic pathway can also be stimulated by ROS. Figure made with Servier Medical Art. Abbreviations: 
AIF: apoptosis-inducing factor, Apaf-1: apoptotic protease-activating factor-1, Bak: bcl-2 antagonist killer 1, 
Bax: bcl-2 associated X protein, Bid: BH3-only pro-apoptotic protein, Casp-: caspase, number refers to the 
type of caspase, Cyt c: cytochrome c, DISC: death-inducing signaling complex, DNA: deoxyribonucleic acid, 
DR: death receptors, EndoG: endonuclease G, IAPs: inhibitor of apoptosis proteins, Omi/HtrA2: high-
temperature requirement A2 serine protease, Smac/Diablo: second mitochondria-derived activator of 
caspases/direct IAP binding protein with low isoelectric point, ROS: reactive oxygen species. 
 
The extrinsic pathway, also called the death receptor pathway, is initiated by binding of 
ligands to their respective death receptors (DR), which activates downstream signaling and 
leads to the formation of the death-inducing signaling complex (DISC) that culminates in 
the activation of caspase-8 (Figure 2). These ligands belong to the tumor necrosis factor 
(TNF) superfamily of cytokines and include TNFα, Fas ligand (FasL), and TNF-related 
apoptosis-inducing ligand (TRAIL). Activation of caspase-8 may activates directly 
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caspase-3 or, when caspase-8 activation is low, mediates caspase-3 activation through a 
process involving mitochondria (55,60,72) (Figure 2). 
 
The second activation corresponds to the intrinsic pathway of apoptosis also designated as 
mitochondria-mediated pathway. Indeed, activated caspase-8 cleaves BH3-only pro-
apoptotic protein (Bid), which interacts with pro-apoptotic proteins bcl-2 associated X 
protein (Bax) and bcl-2 antagonist killer 1 (Bak), inducing the permeabilization of the 
outer mitochondrial membrane and the release of pro-apoptotic proteins from mitochondria 
(72,73) (Figure 2). ROS, particularly H2O2, induce mitochondrial translocation of Bax and 
Bak and release of Cyt c. The more Cyt c is released from mitochondria, the more ROS are 
produced due to OXPHOS impairment (74). Other released proteins are second 
mitochondria-derived activator of caspases/direct IAP binding protein with low isoelectric 
point (Smac/Diablo) and apoptosis-inducing factor (AIF), which triggers caspase-
dependent or caspase-independent cytosolic signaling events (73,75). Within the cytosol, 
Cyt c binds to apoptotic protease-activating factor-1 (Apaf-1) and ATP to form the 
apoptosome complex which recruits and activates the initiator procaspase-9. The activated 
caspase-9 activates the effector caspases-3 and -7, which execute the final steps of 
apoptosis (71,72). Caspase activation is improved by Smac/Diablo and high-temperature 
requirement A2 serine protease (Omi/HtrA2) which are crucial mitochondrial proteins for 
enhanced caspase activation since they antagonize the inhibitory effects of inhibitor of 
apoptosis proteins (IAPs) (55,60,72). The mitochondrial proteins AIF and endonuclease G 
(EndoG) mediate a caspase-independent apoptotic pathway by binding with 
deoxyribonucleic acid (DNA) and thus inducing nuclear chromatin condensation and DNA 
fragmentation (75,76) (Figure 2). In addition to caspase-8, the intrinsic apoptotic pathway 
can also be stimulated by ROS and mtDNA damage, which mediate the permeabilization 
of the mitochondrial outer membrane and the release of pro-apoptotic proteins (55,60) 
(Figure 2). In the set of FAOD there are some studies that report an overexpression of 
apoptotic proteins (48,49,62), including Smac/Diablo and Girdin (48) or Bax (62). So, it 
seems that the intrinsic pathway of apoptosis contributes to the pathogenesis of FAOD, 
including MADD. 
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1.4. The potential contribution of mitochondrial biogenesis to FAOD 
The mitochondrial population constantly migrates back and forth along microtubule tracks, 
in which mitochondria can contact each other end to end and fuse. This mitochondrial 
dynamics, including mitochondrion movement and change of shape and size, is regulated 
by fusion and fission mechanisms (50,77). Since the discovery of the Drosophila mitofusin 
gene (Fzo) in 1997 by Hales and Fuller (78), there have been rapid advances in the 
knowledge of the molecular basis of mitochondrial fusion and fission.  
 
The fusion mechanism is regulated by mitofusins (Mfns), which exist in two identical 
isoforms in mammals, Mfn1 and Mfn2, and localize in the outer mitochondrial membrane. 
(77,79). Several studies demonstrated that cells lacking Mfns or mitochondrial dynamin-
like 120 kDa protein (OPA1), located within the mitochondrial intermembrane space, 
present reduced levels of mitochondrial fusion (80–82). Indeed, when both Mfn1 and Mfn2 
are absent, there is no mitochondrial fusion, resulting in the complete loss of mitochondrial 
tubules and thus in a dramatic decreased mitochondrial functionality (81). Consequently, 
mitochondrial fusion is necessary for the normal function of cells, and perturbations in this 
process might lead to diseases development (77). The fission mechanism involves 
dynamin-related protein 1 (Drp1) and mitochondrial fission 1 protein (Fis1) (77,83,84), 
although other proteins such as endophilin B1 and mitochondrial membrane protein 18 
(MTP18) seem to be involved in this process too (85,86). Indeed, decreased amounts of 
these proteins result in elongation of mitochondrial tubules. These abnormalities in 
mitochondrial morphology are suggestive of defects in fission mechanism (83–86). 
Changes in the regulation of these processes leading to impaired mitochondrial 
functionality have been reported in FAOD (62,67,87). In fact, a down-regulation of Mfn2 
was found in RR-MADD patients (67). 
 
Mitochondrial biogenesis is regulated by many genes related to cellular energy state and 
stress level (50), such as peroxisome proliferator-activated receptor γ coactivator 1 alpha 
(PGC-1α) (88,89). Indeed, all the members of the PGC-1 family (PGC-1α, PGC-1β and 
PGC-1-related coactivator) have been associated with mitochondrial biogenesis, playing a 
central role in this process (54,90–93). These proteins are key regulators of mitochondrial 
content and oxidative metabolism, being also critical in the regulation of glucose, lipid, and 
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energy homeostasis (89,90). In figure 3 a schematic representation of the regulation of 
mitochondrial biogenesis by PGC-1α signaling is presented. 
 
 
Figure 3. Regulation of mitochondrial biogenesis by PGC-1α signaling. Enhanced NAD+/NADH ratio 
stimulates SIRT1 which deacetylates PGC-1α, whereas the increase in AMP/ATP ratio activates AMPK 
which phosphorylates it. Both deacetylation (A) and phosphorylation (B) activate PGC-1α, leading to 
stimulation of specific nuclear factors, such as NRFs, ERRs and PPARs, which activate their target genes. 
NRF1 regulates mtTFA which increases mtDNA gene transcription and replication. This and both NRFs and 
ERRs lead to increase in OXPHOS. ERRs also stimulate FAO and PPAR which has the same effect. SIRT3, 
in NAD+-dependent via, stimulates OXPHOS, FAO and ROS metabolism proteins. All these processes lead 
to mitochondrial biogenesis. Figure made with Servier Medical Art. Abbreviations: AMP: adenosine 
monophosphate, AMPK: AMP-activated protein kinase, ATP: adenosine triphosphate, ERRs: oestrogen-
related receptors, FAO: mitochondrial fatty acid β-oxidation, MnSOD: manganese superoxide dismutase, 
mtDNA: mitochondrial deoxyribonucleic acid, mtTFA: mitochondrial transcription factor A, NAD+: 
nicotinamide adenine dinucleotide, NADH: reduced form of NAD+, NRFs: nuclear respiratory factors, 
OXPHOS: oxidative phosphorylation, PGC-1α: peroxisome proliferator-activated receptor γ coactivator 1 
alpha, PPARs: peroxisome proliferator-activated receptors, ROS: reactive oxygen species, SIRT1: sirtuin 1, 
SIRT3: sirtuin 3. 
 
PGC-1α is a powerful regulator of multiple aspects of mitochondrial gene expression, 
inducing mitochondrial biogenesis and uncoupled respiration (89,91). This protein requires 
transcription factors for the trans-activation of mitochondrial biogenesis genes. Among 
these are the nuclear respiratory factors 1 and 2 (NRF1 and NRF2), peroxisome 
proliferator-activated receptors (PPARs) and others (89,91) (Figure 3). PPARs have 
different subtypes (α, β/δ and γ) that can be stimulated by pharmacological activation and 
are responsible for tissue-specific activation of PGC-1α gene expression (54). NRFs 
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activate the transcription of many genes involved in the respiratory chain function like the 
Cyt c and regulate the mitochondrial transcription factor A (mtTFA). This protein is a 
nuclear factor that acts in the mtDNA, stimulating its replication and transcription (89,91) 
(Figure 3). The expression of other genes including ATP synthase, MnSOD and 
glutathione peroxidase-1 was also increased in cells expressing PGC-1α and PGC-1β 
(89,92). PGC-1α and PGC-1β lead to a similar overexpression of many mitochondrial 
genes, although PGC-1β preferentially induces certain genes involved in the cytosolic ROS 
removal, such as light and heavy subunits of γ-glutamylcysteine synthetase (92). 
The activity of PGC-1α is regulated by post-translational modifications such as acetylation 
and phosphorylation (89). Adenosine monophosphate-activated protein kinase (AMPK) is 
one of the main regulator of cellular metabolism and there has been reported an association 
between the activation of AMPK and the increase in gene expression of PGC-1α and 
mitochondrial proteins (Figure 3), such as Cyt c and mitochondrial uncoupling protein 2 
(UCP2) (89,91,94). Indeed, the increase in PGC-1α may be reached by direct 
phosphorylation of PGC-1α on specific amino acids by AMPK or by binding proteins, 
such as cyclic adenosine monophosphate response element-binding protein and thyroid 
hormones, that bind to specific domains localized inside of the PGC-1α promoter and thus 
stimulating its transcription. AMPK is activated by an increase in adenosine 
monophosphate (AMP) levels (54,89). (Figure 3). There are other kinases involved in 
PGC-1α regulation, including the protein kinase A (PKA) and the p38 mitogen-activated 
protein kinase (MAPK) (95,96). The PKA pathway is stimulated by increased intracellular 
levels of cyclic adenosine monophosphate (cAMP) that activate PKA, which consequently 
phosphorylates and activates sirtuin 1 (SIRT1). SIRT1 activates PGC-1α, leading to 
increased expression of FAO genes (95). Activation of the p38 MAPK pathway stimulates 
upstream transcription factors of the PGC-1α gene, thus enhancing its promoter activity 
and leading to increased PGC-1α mRNA levels (96). 
Sirtuins are deacetylases that regulate responses to a variety of stresses, like calorie 
restriction and metabolic stress, via NAD+-dependent deacetylation (97). Sirtuin 3 (SIRT3) 
is located into mitochondria where it regulates the acetylation levels of a large range of 
substrates including proteins from FAO, OXPHOS and ROS metabolism (98,99) (Figure 
3), although the exact mechanism is still somewhat unclear (54). Mice lacking SIRT3 
exhibit hallmarks of FAOD like reduced ATP levels during fasting. Interestingly, these 
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mice showed accumulation of long-chain acylcarnitines and TG, suggesting that oxidation 
of long-chain acyl substrates was impaired. However, this defect appeared to be specific, 
because citrate synthase (CS) activity, an indicator of mitochondrial function, was not 
altered. Indeed, the long-chain acyl-CoA dehydrogenase (LCAD) in these mice was not 
deacetylated during fasting, which results in reduced enzymatic activity of LCAD. These 
findings indicate that SIRT3 is necessary for LCAD deacetylation, particularly of lysine 
forty-two on its amino acids chain. So, reversible deacetylation of mitochondrial enzymes 
by SIRT3 may be considered a novel metabolic regulatory mechanism for FAO (98). In 
addition to this study, others focused on SIRT1 demonstrated the importance of 
deacetylation mechanism as a modulator of mitochondrial metabolism (100,101). SIRT1 
also enhances FAO protecting against diet-induced metabolic disorders (100). Some 
studies have demonstrated an association of these proteins with FAOD pathogenesis 
(67,102). Indeed, it was reported a down-regulation of SIRT3 (67) and an overexpression 
of peroxisome proliferator-activated receptor α (PPARα) (102) in RR-MADD patients. 
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2. Aims 
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The aim of the present study was to characterize the mitochondrial dynamics in multiple 
acyl-CoA dehydrogenase deficiency (MADD) in order to better understand the molecular 
mechanisms underlying the disease pathogenesis. In this way, it was our purpose to 
evaluate the contribution of mitochondrial biogenesis, metabolic remodeling and 
antioxidant defense mechanisms to MADD phenotype, in fibroblasts isolated from skin 
biopsies of patients with distinct clinical outcomes. Other biological processes such as 
autophagy and apoptosis were also evaluated. The integration of all data added new 
insights on the understanding of the molecular pathways underlying the large range of 
phenotypes observed in MADD patients, which may eventually lead to the identification of 
molecular targets for more efficient therapeutic strategies. 
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3. Materials and Methods 
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3.1. Experimental design 
In order to fulfill the aim of this study, the sequential steps described in figure 4 were 
followed. Immunoblotting, immunocytochemistry and spectrophotometric assessment of 
enzymatic activities were the experimental procedures selected to better understand the 
mitochondrial dynamics in multiple acyl-CoA dehydrogenase deficiency (MADD). 
 
 
Figure 4. Experimental design followed at the present work. Skin biopsy was done in all MADD patients and 
controls (heathy individuals aged-matched with patients) to obtain cultured fibroblasts. These cells were then 
analyzed by immunoblotting to semi-quantify the amount of specific proteins, by immunocytochemistry to 
estimate the mitochondrial density and by specific spectrophotometric assays to measure the activity of key 
metabolic enzymes. 
 
 
3.2. Samples characterization 
Samples from four MADD patients and four healthy individuals, with no apparent related 
disease and aged-matched, were used. All the patients presented mutations in the ETFDH 
gene and are non-responsive to riboflavin therapy. Two patients presented mild forms of 
MADD (MADD1 and MADD2), while the other two (MADD3 and MADD4) had severe 
forms. The MADD1 and MADD2 patients are both homozygous for the mutation p.R175H 
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in ETFDH, corresponding to the well described late onset form (type III) of MADD. The 
MADD3 patient is homozygous for the mutation p.X618QextX14 in ETFDH while 
MADD4 patient is compound heterozygous for p.X618QextX14 and p.E412X, also in 
ETFDH. These two patients (MADD3 and MADD4) phenotypically correspond to the 
early onset form of MADD. Both controls and patients samples were used, anonymously, 
after each subject/legal guardian gave written informed consent. 
 
 
3.3. Cell culture and cell extracts preparation 
Skin fibroblasts from MADD patients and healthy individuals (controls) were grown in 
Dulbecco's Modified Eagle Medium (DMEM 21885, Gibco™, Thermo Fischer Scientific®) 
supplemented with 10 % fetal calf serum, 1 % penicillin, streptomycin and fungizone in 75 
cm2 culture flasks at 37 ºC in a 5 % CO2 incubator. Three culture flasks from each sample, 
corresponding approximately to 103 cells, were grown to pre-confluence status. The pellets 
of cultured fibroblasts were dissolved in lysis buffer (100 mM potassium phosphate, pH 
7.4, 0.1 % (v/v) Triton X-100) and then the cell suspension was homogenized in a tight-
fitting Potter-Elvejhelm. The final solution was stored at -80 ºC for further analyzes. 
 
 
3.4. Total protein quantification 
An aliquot of cell homogenate was used for total protein quantification using the 
commercial kit DC Protein Assay (Bio-Rad®, Hercules, CA, USA). This kit is based on 
Lowry et al. (103) assay, on which proteins react with copper in an alkaline solution and 
then occurs the reduction of Folin reagent by the copper-treated protein, leading to the 
formation of a blue color with maximum absorbance at 750 nm. In this way, a calibration 
curve with standard solutions of bovine serum albumin (BSA) at concentrations between 
0.312 and 10 mg/mL was made. Equal volumes (5 μL) of sample or standard were used for 
the experimental procedure according to manufacturer’s recommendations and the 
absorbance was read at 750 nm in a microplate reader (Multiskan GO, Thermo Fischer 
Scientific®, Northumberland, UK). 
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3.5. Protein precipitation 
The amount of total protein in cell extracts of patient MADD4 was much lower than in the 
other samples. So, before the analysis of this sample by sodium dodecyl sulphate-
polyacrylamide gel electrophoresis (SDS-PAGE), protein was precipitated. Briefly, the 
sample volume corresponding to 20 μg of protein was dissolved in four times that volume 
of cold acetone (-20 ºC) and then incubated overnight at -20 ºC. After that, the sample was 
centrifuged 10 minutes at 17,000xg and 4 ºC and then the supernatant was discharged. The 
protein pellet was allowed to dry at room temperature and finally dissolved in 0.5 M Tris-
HCl pH 6.8. 
 
 
3.6. SDS-PAGE and Western blotting 
To analyze the expression of target proteins, equal amounts of protein (20 μg) from each 
sample were dissolved in loading buffer (0.5 M Tris-HCl pH 6.8, 4 % (w/v) SDS, 15 % 
(v/v) glycerol, 1 mg/mL bromophenol blue and 20 % (v/v) β-mercaptoethanol) and heated 
5 minutes at 100 ºC and then loaded in a 12.5 % SDS-PAGE gel prepared according to 
Laemmli (104). The gels were run for 45 minutes at 180 V in running buffer (250 mM 
glycine, 25 mM Tris, pH 8.6 and 0.1 % (w/v) SDS). The resolved proteins were transferred 
to a nitrocellulose membrane (Amersham™ Protran™, GE Healthcare, Germany, 0.45 μm 
porosity) for 2 hours at 200 mA. The buffer used contained 192 mM glycine, 25 mM Tris, 
pH 8.3 and 20 % (v/v) methanol and the efficacy of transfer was confirmed by Ponceau S 
staining. After that, membranes were blocked in order to avoid unspecific binding with 5 
% (w/v) nonfat dry milk in Tris-buffered saline (TBS) with Tween 20 (TTBS; 100 mM 
Tris, 1.5 mM NaCl, pH 8.0 and 0.05 % (v/v) Tween 20) for 1 hour at room temperature 
with shaking. Next, the membranes were incubated with the primary antibody, diluted 
1:1000 in 5 % (w/v) nonfat dry milk in TTBS for 2 hours at room temperature or overnight 
at 4 ºC. The primary antibodies used were rabbit monoclonal anti-APG5L/ATG5 
(ab108327), rabbit monoclonal anti-Bax (ab32503), rabbit monoclonal anti-Bcl2A1 
(ab33862), rabbit polyclonal anti-ETFDH (ab91508), rabbit polyclonal anti-GAPDH 
(ab9485), rabbit polyclonal anti-MnSOD (ab13533), rabbit polyclonal anti-mtTFA 
(ab47548) and rabbit polyclonal anti-PGC1 alpha (ab54481) from Abcam (Cambridge, 
34 
UK), rabbit monoclonal anti-Caspase-3 cleaved (9664S) and rabbit monoclonal anti-SirT3 
(2627S) from Cell Signaling Technology (MA, USA) and rabbit polyclonal anti-Atpalpha 
(GTX123137) from GeneTex Inc. (US). Following, the membranes were washed three 
times (10 minutes each) with TTBS to remove the unbind antibodies. Next, the membranes 
were incubated with the appropriate secondary horseradish peroxidase-conjugated antibody 
(anti-mouse or anti-rabbit, NA931 or NA934, respectively; GE Healthcare, UK), diluted 
1:1000 with 5 % (w/v) nonfat dry milk in TTBS, for 1 hour at room temperature with 
shaking. The membranes were washed three times (10 minutes each) again with TTBS and 
exposed with enhanced chemiluminescence ECL reagent (WesternBright™ ECL, advansta, 
CA, USA) followed by exposure to X-ray films (Kodak Biomax Light Film, Sigma®, St. 
Louis, USA). Film images were acquired using GelDoc XR system (Bio-Rad®, Hercules, 
CA, USA) and semi-quantitative analysis of optical density (OD) was performed with 
QuantityOne® 1-D Analysis Software version 4.6.3 (Bio-Rad®, Hercules, CA, USA). 
Exceptionally, for ATG5 protein the detection method used was the fluorescent one since 
this technique is more sensitive than chemiluminescence. So, the secondary antibody used 
was fluorophore-conjugated (goat anti-rabbit 926-68071 diluted 1:5000 in 5 % (w/v) 
nonfat dry milk in TTBS) and after the third wash with Tris-buffered saline (TBS; 100 mM 
Tris, 1.5 mM NaCl, pH 8.0) instead of TTBS, the fluorescence of membranes was 
automatically measured using the Odyssey Infrared Imaging System (LI-COR® 
Biosciences, US). 
 
 
3.7. Determination of the content of carbonylated proteins by Slot-blot 
The content of carbonyl groups in proteins was evaluated according to Robinson et al. 
(105) with some modifications. Firstly, a given volume (V) from each sample containing 
10 μg of protein was mixed with 12 % (w/v) SDS (V) and 20 mM 2,4-
dinitrophenylhydrazine (DNPH) prepared in 10 % (v/v) trifluoroacetic acid (2V). The 
reaction between carbonyl groups and DNPH leads to the formation of 2,4-dinitrophenil 
(DNP) hydrazone which can be detected by immunoblotting. Next, sample mixtures were 
incubated in the dark at room temperature for 30 minutes. The addition of 2 M Tris with 18 
% (v/v) β-mercaptoethanol (1.5V) stopped the reaction. Two different dilutions, 1:75 and 
1:100, were prepared in TBS. After this, 100 μL of each sample dilution were transferred 
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to a nitrocellulose membrane (Amersham™ Protran™, GE Healthcare, Germany, 0.45 μm 
porosity) using a Slot-blot system, according to manufacturer’s instructions. The 
nitrocellulose membranes were first activated by immersion on 10 % (v/v) methanol 
solution for 5 seconds and placed in distilled water until transference procedure. The 
immunodetection was performed as described above for Western blotting. The primary 
antibody used (mouse monoclonal anti-DNP; MAB2223, Millipore) was diluted 1:1000 in 
5 % (w/v) nonfat dry milk in TTBS and incubated for 1 hour at room temperature with 
shaking. 
 
 
3.8. Immunocytochemistry  
Immunocytochemistry was performed to obtain information about mitochondrial density in 
cultured fibroblasts from MADD patients. Briefly, fibroblasts were grown in coverslips 
inside 6-well plates at 37 ºC in a 5 % CO2 incubator until they reach approximately a 60 % 
confluence. At that time, the culture medium (see section 3.3) was removed and fibroblasts 
were washed twice in Phosphate-buffered saline (PBS, P4417-100TAB, Sigma®; 0.01 M 
phosphate buffer, 0.0027 M potassium chloride, 0.137 M sodium chloride, pH 7.4) and 
fixed for 10 minutes at room temperature with 3.7 % (v/v) formaldehyde solution prepared 
in PBS. After fixation, fibroblasts were washed three times (10 minutes each) with PBS. 
Coverslips were stored at 4 ºC in PBS overnight due to convenience issues. In the next day, 
fibroblasts were permeabilized for 10 minutes with 0.2 % (v/v) Triton X-100 in PBS and 
then washed three times (10 minutes each) with PBS. Nonspecific binding was blocked 
with blocking solution (5 % (w/v) BSA and 1 % (w/v) goat serum in PBS) for 30 minutes. 
After wash with PBS, fibroblasts were incubated with rabbit polyclonal anti-COX IV 
(ab16056, Abcam, Cambridge, UK) diluted 1:1000 in blocking solution at room 
temperature for 1 hour in a wet chamber. Fibroblasts were then washed three times (10 
minutes each) with PBS and incubated with the secondary antibody diluted 1:500 in 
blocking solution at room temperature for 30 minutes in a dark and wet chamber. The 
antibody used was goat anti-rabbit Alexa Fluor® 594 (A-11037, Thermo Fischer 
Scientific®). After three washes (10 minutes each) with PBS, coverslips were incubated 
with 50 μL of Hoechst 33258 (Polysciences Europe GmbH, Eppelheim, Germany) diluted 
1:8000 for 1 minute at room temperature in a dark and wet chamber to stain the nuclei. 
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Then, two washes with PBS and one with distilled water (10 minutes each) were done and 
fibroblasts were mounted on the slide with Mowiol 4-88 (Sigma-Aldrich Química) and 
they were let to dry. Slides were stored protected from the light at 4 ºC. Images were 
acquired using an Olympus IX-81 inverted epifluorescence microscope (Olympus 
Portugal–Opto-Digital Tecnologias, S.A., Lisboa, Portugal), with a x100 objective. 
 
 
3.9. Spectrophotometric activity assays 
3.9.1. ATP synthase activity 
The activity of respiratory chain complex V was measured according to Simon et al. (106). 
The phosphate produced by hydrolysis of ATP reacts with ammonium molybdate in the 
presence of reducing agents to form a blue color complex. The intensity of this complex is 
proportional to the concentration of phosphate in solution. Equal volumes (15 μL) from 
each sample were dissolved in reaction buffer (0.2 M KCl, 3 mM MgCl2, 10 mM Tris-HCl, 
pH 8.4) and incubated at 30 ºC for 1 minute. Then an equal volume of 0.1 M ATP was 
added and incubated for 1 minute at 30 ºC. The reaction was stopped by the addition of 30 
μL of 3 M tricloroacetic acid. After centrifugation at 9,000xg and 4 ºC for 10 minutes, 125 
μL of supernatant were mixed with 625 μL of test solution (0.37 M H2SO4, 0.01 M 
ammonium molybdate and 0.1 M ferrous sulphate) and then incubated for 15 minutes at 
room temperature. In parallel, a calibration curve with standard solutions of potassium 
dihydrogen phosphate (KH2PO4) at concentrations between 0.0 and 1.0 mM were prepared. 
Oligomycin was used as an ATP hydrolase inhibitor. The absorbance was read at 610 nm 
in a microplate reader (Multiskan GO, Thermo Fischer Scientific®, Northumberland, UK). 
Then, the absorbance values were converted to concentration (mM) per minute from the 
equation of calibration curve and then divided by total protein in order to obtain the 
enzymatic activity values (mmol Pi.min-1.mg-1) on each sample. 
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3.9.2. Citrate synthase activity 
The activity of citrate synthase was determined according to Coore et al. (107). This 
method evaluates the presence of free thiol groups in CoASH by its reaction with 5,5’-
dithiobis-(2-nitrobenzoate) (DTNB). The resulting 2-nitro-5-thiolbenzoate (TNB) anion 
has a strong absorption at 412 nm, allowing the reaction to be followed 
spectrophotometrically. Firstly, the reaction mixture including 200 mM Tris buffer pH 8.0, 
10 mM acetyl-CoA, 10 mM DTNB and 0.1 % (v/v) Triton X-100 was prepared. Then, 
equal volumes (5 μL) from each sample (except for MADD4 for which the volume used 
was 10 μL) were incubated with 190 μL (185 μL for MADD4) of reaction mixture and the 
absorbance was read at 412 nm for approximately 2 minutes at 30 ºC in a microplate reader 
(Multiskan GO, Thermo Fischer Scientific®, Northumberland, UK). Then, equal volumes 
(5 μL) of 10 mM oxaloacetate were added to each well of the microplate and the 
absorbance was again read at 412 nm for approximately 2 minutes at 30 ºC. The 
absorbance values of the last assay were plotted against time and the slope of the equation 
((ΔA412)/min) was divided by the extinction coefficient of TNB at 412 nm (13.6 mM-
1.cm-1). Finally, the values obtained were divided by total protein in order to obtain the 
enzymatic activity values (nmol.min-1.mg-1) on each sample. 
 
 
3.10. Statistical analysis 
All the data is presented as mean ± standard deviation (SD) of replicates of n = 4 for 
controls and replicates for each patient. The statistical analysis between MADD patients 
and controls was performed using the unpaired students t-test from GraphPad Prism® 
software for Windows (version 6.0). The level of significance was set at 5 % (p-value < 
0.05). 
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4.1. Analysis of ETFDH expression 
To characterize the expression of electron transfer flavoprotein dehydrogenase (ETFDH) in 
MADD patients and relate it with the mutation in the ETFDH gene, Western blotting was 
performed. The results of ETFDH expression obtained for the controls and MADD patients 
are presented in figure 5. 
 
 
Figure 5. Expression levels of ETFDH measured by Western blotting in total homogenates of skin 
fibroblasts from controls and MADD patients. MADD1 and MADD2 correspond to a mild form while 
MADD3 and MADD4 have severe form of MADD. Above the graph is presented a representative image of 
the Western blots obtained. The values (mean ± SD) are expressed in arbitrary units of optical density (OD). 
** p < 0.01. 
 
Only patients with the severe form of MADD (MADD3 and MADD4) presented a 
significant difference on ETFDH expression levels compared to controls (p < 0.01). This is 
in accordance with what is expected based on the nature of the disease-causing genotype. 
The mutation p.E412X leads to a truncated protein and p.X618QextX14 to an extended 
protein that are most probably degraded/partially degraded by cell PQC system. Mild 
patients (MADD1 and MADD2) are homozygous for a missense mutation that although 
impairing ETF/ETFDH complex functionality, did not result in a significant decrease of 
ETFDH expression levels. 
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4.2. Effect of MADD on cells’ metabolic status 
The ETFDH enzyme links the β-oxidation with the oxidative phosphorylation (OXPHOS) 
through the transfer of electrons from acyl-CoA dehydrogenases to ubiquinone (CoQ) (14). 
In order to evaluate the impact of this enzyme’s deficit or non-functionality, the levels of 
glyceraldehyde-3-phosphate dehydrogenase (GAPDH), and the levels and activity of ATP 
synthase were measured. Figure 6 presents the results obtained. 
 
 
Figure 6. Effect of ETFDH deficiency on the metabolic status of skin fibroblasts’ homogenate. MADD1 and 
MADD2 correspond to a mild form while MADD3 and MADD4 have severe form of MADD. Expression 
levels of ATP synthase α subunit measured by Western blotting; above the graph is presented a 
representative image of the Western blots obtained (A). ATP synthase activity was spectrophotometrically 
measured and values are expressed in mmol Pi.min-1.mg-1 (B). Expression levels of GAPDH measured by 
Western blotting; above the graph is presented a representative image of the Western blots obtained (C). 
Ratio between GAPDH and ATP synthase α subunit (D). The values (mean ± SD) are expressed in arbitrary 
units of optical density (OD) for A and C. * p < 0.05; ** p < 0.01; *** p < 0.001. # The value obtained for 
this sample was below the detection limit so the value is hide in the graph. 
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Western blotting analysis of ATP synthase α subunit showed no significant differences for 
MADD patients compared to controls, despite a tendency towards reduced levels for 
MADD1, MADD2 and MADD4 (Figure 6-A). The activity of ATP synthase was also 
measured, and lower values were noticed for all patients with the exception of MADD2 
(Figure 6-B). Unfortunately for MADD4 the ATP synthase activity was not possible to 
measure because of the low protein concentration levels obtained in the samples. 
Curiously, the protein levels of GAPDH were significantly lower in all patients compared 
to controls (Figure 6-C). When the ratio between GAPDH and ATP synthase α subunit 
expression levels was calculated, no significant differences among MADD patients and 
controls were observed, except for MADD3 who showed significantly lower values than 
controls (p < 0.05, Figure 6-D). 
 
 
 
4.3. Effect of MADD on oxidative stress 
In order to evaluate the oxidative status in MADD, protein carbonylation was assessed by 
Slot-blot. In parallel, the axis sirtuin 3 (SIRT3) - manganese superoxide dismutase 
(MnSOD) was studied by Western blotting. In figure 7 are showed the results obtained for 
MADD patients and controls. 
 
 
Data evidenced no alterations in the content of carbonylated proteins (Figure 7-A). For the 
other hand, SIRT3 levels were significantly lower in MADD patients compared to controls, 
except for MADD1 (Figure 7-B). In opposite, no significant differences were observed for 
the MnSOD levels (Figure 7-C). However, a significant decrease of MnSOD was noticed 
for MADD3 compared to controls (p < 0.001). 
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Figure 7. Effect of ETFDH deficiency on protein carbonylation (A), SIRT3 (B) and MnSOD (C) levels in 
total homogenates of skin fibroblasts assessed by immunoblotting. MADD1 and MADD2 correspond to a 
mild form while MADD3 and MADD4 have severe form of MADD. Above each graph is presented a 
representative image of the immunoblots obtained. The values (mean ± SD) are expressed in arbitrary units 
of optical density (OD). * p < 0.05; ** p < 0.01; *** p < 0.001. 
 
 
 
4.4. Effect of MADD on mitochondrial biogenesis and mitophagy 
In order to characterize the mitochondrial dynamics in MADD pathogenesis, protein 
markers of mitochondrial biogenesis and mitophagy were selected to be evaluated. The 
activity of the mitochondrial enzyme citrate synthase (CS) was spectrophotometrically 
assessed once this enzyme is considered a rough indicator of the number of mitochondria 
content on cells (108). The expression levels of the mitochondrial transcription factor A 
(mtTFA) and its regulator peroxisome proliferator-activated receptor γ coactivator 1 alpha 
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(PGC-1α) were measured by Western blotting. Figure 8 presents the results of the 
mitochondrial dynamics analysis obtained for MADD patients and controls. 
 
 
Figure 8. Effect of ETFDH deficiency on mitochondrial biogenesis and mitophagy markers assessed in total 
homogenates of skin fibroblasts. MADD1 and MADD2 correspond to a mild form while MADD3 and 
MADD4 have severe form of MADD. Citrate synthase activity was spectrophotometrically measured and the 
values (mean ± SD) are expressed in nmol.min-1.mg-1 (A). Expression levels of mtTFA (B), PGC-1α (C) and 
ATG5 (D) measured by Western blotting; above each graph is presented a representative image of the 
Western blots obtained. The values (mean ± SD) are expressed in arbitrary units of optical density (OD) for 
B, C and D. * p < 0.05; ** p < 0.01; *** p < 0.001. # The value obtained for this sample was below the 
detection limit so the value is hide in the graph. 
 
The activity of CS was 2-fold higher in MADD3, compared to controls (p < 0.001; Figure 
8-A). No significant CS activity differences were noticed for mild MADD patients. 
Unfortunately, we were unable to measure CS activity in MADD4 due to the low protein 
concentration in the corresponding samples. The levels of mtTFA were only significantly 
46 
higher in MADD4 (p < 0.05; Figure 8-B), although some tendency towards increased 
levels was noticed for the other MADD patients. Protein levels of PGC-1α were 
significantly lower in all MADD patients than in controls (p < 0.01; Figure 8-C). So, data 
suggest that mitochondrial biogenesis is down-regulated in MADD patients despite the 
higher levels of mtTFA detected in a patient with a severe phenotype. 
The contribution of autophagy to mitochondrial dynamics was assessed by measuring the 
content of autophagy protein 5 (ATG5) by Western blotting. Significantly lower levels 
were observed in mild MADD patients compared to controls (p < 0.05; Figure 8-D), 
without significant differences noticed for patients with the severe phenotype (MADD3 
and MADD4). 
 
 
In addition to the analysis of these proteins detected by Western blotting, 
immunocytochemistry was also applied to estimate the mitochondrial density (preliminary 
studies). This was done targeting subunit IV of cytochrome c oxidase (COX IV), which 
localizes in the inner mitochondrial membrane and is ubiquitous in human tissues. This 
subunit is essential for cytochrome c oxidase (C-IV) assembly and functionality and thus 
for oxidative phosphorylation (109). The results from immunofluorescence are presented 
in figure 9. 
 
 
The immunofluorescence images obtained for COX IV suggest that both mild and severe 
MADD patients apparently have COX IV in a more restricted area compared to controls. 
Patients present small dots more intense near the nucleus, while in the controls they are 
more spread alongside the fibroblasts (Figure 9). In fact, we expected COX IV staining to 
be more abundant near the nucleus since mitochondria preferentially localize there. These 
preliminary studies suggest reduced mitochondrial density in MADD patient compared to 
controls, agreeing with the Western blot results for PGC-1α (Figure 8-C), a key regulator 
of mitochondrial biogenesis (88,89). 
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Figure 9. Effect of ETFDH deficiency on mitochondrial density in cultured skin fibroblasts from MADD 
patients. For control, mild and severe skin fibroblasts is presented a representative image of COX IV (red, 
Alexa Fluor® 594) and the merge between COX IV and the cell nuclei (blue, Hoechst 33258). Negative 
controls are presented in Appendix section. All images were obtained with a 100x magnification in an 
Olympus IX-81 inverted epifluorescence microscope. The scale bar of images is 20 μm. 
 
 
 
4.5. Effect of MADD on apoptosis 
In the present study we also evaluated the contribution of apoptotic pathways to MADD 
pathogenesis. Since our focus was on mitochondria, expression levels of proteins from the 
intrinsic pathway was measured, specifically bcl-2 associated X protein (Bax) and bcl-2 
related protein A1 (Bcl-2A1). The expression levels of cleaved caspase-3 (Casp-3), which 
is the active form of the enzyme, were also measured by Western blotting. In figure 10 are 
presented the results obtained. 
 
 
The expression levels of the pro-apoptotic protein Bax were not significantly different in 
MADD patients compared to controls despite an overall tendency to reduced levels (Figure 
10-A). MADD4 patient showed significantly lower levels compared to controls (p < 0.05). 
No significant differences of Bcl-2A1 protein levels were found among MADD patients 
and controls (Figure 10-B). The ratio between these two proteins (Bax:Bcl-2A1) was 
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significantly lower in severe MADD patients compared to controls (Figure 10-C). No 
significant differences of the ratio between Bax and Bcl-2A1 were noticed for mild MADD 
patients. Curiously, the protein levels of Casp-3 were significantly higher only for MADD4 
(p < 0.0001; Figure 10-D). The protein levels for the other subjects were not detectable by 
Western blot. 
 
 
Figure 10. Effect of ETFDH deficiency on the content of Bax (A) and Bcl-2A1 (B), ratio between Bax and 
Bcl-2A1 (C) and Casp-3 (D) measured by Western Blotting in total homogenates of skin fibroblasts. 
MADD1 and MADD2 correspond to a mild form while MADD3 and MADD4 have severe form of MADD. 
Above each graph is presented a picture of the Western blots obtained. The values (mean ± SD) are 
expressed in arbitrary units of optical density (OD). * p < 0.05; *** p < 0.001; **** p < 0.0001. 
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5. Discussion 
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Multiple acyl-CoA dehydrogenase deficiency (MADD) is a rare disorder inherited in an 
autosomal recessive pattern which presents heterogeneous clinical phenotypes (29,30). 
Despite some degree of genotype-phenotype correlation, observed clinical spectrum 
suggests that other/specific molecular and cellular mechanisms may have a key role in 
MADD pathogenesis, in addition to mutations in ETFA, ETFB and ETFDH genes (26,33). 
Indeed, previous studies from our research group find that the mitochondrial proteome of 
patients with the same disease-causing genotype present different protein profiles. 
Moreover, patients with mild forms of MADD share some distinct protein signatures with 
severe forms and at the same time have distinctive expression patterns (unpublished data). 
These findings for MADD patients are consistent with those observed for LCHAD 
(unpublished data) and SCAD (110) deficiencies. In this way, our aim was to relate the 
regulation of biological processes associated to mitochondrial homeostasis with the 
severity of MADD, due to mutations on the gene that codifies the protein electron transfer 
flavoprotein dehydrogenase (ETFDH), evidencing similarities and differences. The 
integrated analysis of our data will help to better understand and characterize the molecular 
mechanisms underlying the mitochondrial dysfunction observed in these MADD patients. 
 
To address the biological processes that regulate mitochondria homeostasis cultured skin 
fibroblasts from MADD patients were chosen. Cells isolated from other tissues as cardiac 
or skeletal muscles would be preferred since are more reliant on mitochondrial β-oxidation 
for energy purposes and fatty acids are preferential substrates (42,102,111,112). However, 
cultured skin fibroblasts are considered an attractive sample since skin biopsy is minimally 
invasive compared to other tissue biopsies and a large amount of cell material can be 
obtained (113,114). In fact, fibroblasts can be stored for long periods giving possibility of 
confirmatory posterior studies when new diagnostic tools become available. Moreover, this 
sample allows enzymatic measurements along with other biochemical and genetic analyzes 
(113). There have been reported several studies of mitochondrial proteome profiling in 
cultured fibroblasts for FAOD pathogenesis research (46,48,67,115,116). 
In this way, cultured skin fibroblasts from four MADD patients, two with mild forms 
(MADD1 and MADD2) and two with severe forms (MADD3 and MADD4), were studied. 
MADD1 and MADD2 patients are both homozygous for the mutation p.R175H that 
introduces a substitution of arginine 175 with histidine in the FAD binding domain of 
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ETFDH (46). In opposite, MADD3 is homozygous for the mutation p.X618QextX14 
which results in a protein extension of thirteen amino acids in C’-terminal of ETFDH due 
to a mutation in the stop codon that introduces another one that codifies glutamine 
(X618Q) and allows the continuous of translation until it reaches a different stop codon. 
MADD4 patient is compound heterozygous for p.X618QextX14 and p.E412X, which 
results in a truncated protein due to a mutation in the codon that codifies aspartate and 
introduces a premature stop codon (E412X). While the first two patients harbored a 
missense variation that impairs ETF/ETFDH complex functionality, the other two 
presented frameshift and nonsense mutations which lead to altered ETFDH protein that is 
most probably degraded/partially degraded by cell PQC system. Our results for the 
ETFDH expression levels detected by Western blotting corroborate these findings since 
MADD3 and MADD4 patients showed a significant decrease of the protein expression 
compared to controls, whereas MADD1 and MADD2 did not show significant decreased 
levels (Figure 5). Previous studies reported an absence of this protein in both severe and 
mild MADD forms (46,48). However, ETFDH absence in the study from Rocha et al. (48) 
was determined in isolated mitochondria, suggesting that this protein was not correctly 
transported to the mitochondria. Our results do not exclude the possibility of ETFDH 
absence in mitochondria in severe forms of MADD since we analyzed whole cell 
homogenates. Yotsumoto et al. (46) have also performed the analysis of ETFDH 
deficiency in whole cell homogenates, although the mild patients studied by them have a 
different genotype from ours and they probably used a different primary antibody targeting 
ETFDH protein. A more robust analysis of ETFDH protein in these patients may be 
considered, through measurement of enzyme activity because it correlates with 
functionality and there have been efforts to associate the enzyme activity with disease 
phenotypes (117). 
 
In overall, we found that the ETFDH deficiency results in the down-regulation of 
mitochondrial biogenesis in MADD cultured skin fibroblasts evidenced by the significant 
decreased levels of peroxisome proliferator-activated receptor γ coactivator 1 alpha (PGC-
1α) reported in all patients. Similarly, significant decreased levels of glyceraldehyde-3-
phosphate dehydrogenase (GAPDH) in all MADD patients points to a metabolic 
adaptation in consequence of ETFDH deficiency. For the other biological processes 
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assessed we found differences among MADD patients. In fact, several proteins from these 
processes presented different expression levels among patients with the same genotype. 
 
We hypothesized based on previous studies that ETFDH deficiency has impact on 
mitochondrial biogenesis and mitophagy, since these mechanisms are usually activated to 
counteract the disease-related mitochondrial dysfunction. Mitochondrial biogenesis was 
down-regulated, evaluated by significant decreased levels of PGC-1α in all MADD 
patients (Figure 8). To consolidate these results, immunocytochemistry studies were also 
performed in order to evaluate mitochondrial density. The preliminary qualitative data 
suggest decreased mitochondrial density (Figure 9), being in accordance with the down-
regulation of PGC-1α. Different regulation mechanisms of this key regulator of 
mitochondrial biogenesis have been reported in several studies (102,118,119). Up-
regulation of PPAR genes was reported in both MADD and riboflavin-responsive MADD 
(RR-MADD) patients, suggesting a compensatory mechanism of cells to counteract the 
damaged mitochondria inefficient in lipid metabolism (102,118), whereas a down-
regulation of PGC-1α was also reported (119). On the other hand, mitophagy was found 
differently expressed in MADD patients. In fact, only patients with mild forms of MADD 
showed significant reduced levels of autophagy protein 5 (ATG5). This autophagic protein 
is essential for the autophagosome formation being considered a good mitophagy marker 
(52). Thus, the reduced levels of this protein in MADD1 and MADD2 suggest that 
mitophagy is down-regulated in these two mild MADD patients. However, this down-
regulation of ATG5 did not seem to be correlated with an increased mitochondrial density 
considering the decreased PGC-1α levels in all patients. In accordance with these results, 
we found no alterations in citrate synthase (CS) activity for mild MADD patients. Thus, 
this corroborates with no increases in mitochondrial density since CS is considered as a 
good indicator of the number of mitochondria/mitochondrial mass on cells (108). 
However, severe MADD patients presented significant changes which require further 
analysis of these biochemical processes. In fact, MADD3 showed increased CS activity 
which may be explained by a compensatory mechanism with up-regulation of Krebs cycle, 
while MADD4 showed significantly higher levels of mitochondrial transcription factor A 
(mtTFA). Mitochondrial morphology and number should be evaluated in order to better 
understand the differences found among MADD patients in these processes. Mitotracker 
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assessment and markers of fusion/fission events may be considered to evaluate other signs 
of different phases of mitophagy. In fact, inhibition of fusion detected by decreased levels 
of mitofusin 2 (Mfn2), with increased mitophagy and fractionation were previously 
reported in RR-MADD patients (102). 
 
PGC-1α is a key regulator of a huge variety of mitochondrial proteins (89). Indeed, down-
regulation of PGC-1α have been associated with down-expression of several mitochondrial 
enzymes including FAO enzymes and sirtuin 3 (SIRT3) (119). Our findings evidenced a 
down-regulation of SIRT3 in MADD patients (Figure 7), being consistent with previous 
studies (67,119). SIRT3 is an essential mitochondrial regulator enzyme since it controls the 
activity of key metabolic and antioxidant enzymes by direct deacetylation and also 
indirectly by decreasing ROS-induced stability of hypoxia-inducible factor-1α (HIF-1α) 
(98,120). Thus, SIRT3 can act as a ROS suppressor due to its role on deacetylation and 
consequently activation of manganese superoxide dismutase (MnSOD) (121). No 
differences were noticed for the MnSOD levels, except for MADD3 who showed a 
significant decrease compared to controls. There are no straight results for MnSOD levels 
in literature for MADD patients. In fact, some studies reported down-regulation of MnSOD 
in RR-MADD patients (67,111), while other demonstrated an overexpression of this 
antioxidant enzyme for both mild and severe forms of MADD (48). Given the decreased 
levels of SIRT3 in almost all patients we were expecting similarly a down-regulation of 
MnSOD levels. However, the regulation of MnSOD by SIRT3 may not be sufficient to 
influence protein levels and thus enzymatic activity of MnSOD should be considered. 
Curiously, no significant differences on the content of carbonylated proteins were found in 
MADD patients, proving no differences in ROS production. We were expecting 
significantly higher levels of ROS and consequently of carbonylated proteins in MADD 
patients because it was previously described that MADD as other FAOD are associated 
with increased ROS production (8,67,118). The different results obtained for MnSOD and 
carbonylated proteins levels suggest that other assays should be performed to better 
characterize the oxidative status associated with ETFDH deficiency. 
 
Previous studies have demonstrated a metabolic reprograming towards glycolysis with up-
regulated genes and proteins of glycolysis and down-regulation of oxidative 
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phosphorylation (OXPHOS) in MADD and RR-MADD patients (48,67,118). We found 
significantly lower levels of GAPDH in all MADD patients (Figure 6). This protein plays 
an important role in glycolysis and gluconeogenesis (122). Our results for GAPDH were 
not consist with the previous mentioned (48,118). These studies were performed in isolated 
mitochondria, whereas we analyzed whole cell homogenates suggesting a possible 
explanation for the different results mentioned. In fact, overexpression of GAPDH in 
mitochondria has been associated with apoptotic events (123,124). Fibroblasts were 
cultured in medium containing glucose, pyruvate and large amounts of amino acids and 
vitamins, so we were expecting an increase in glycolytic enzymes. However, the overall 
down-regulation of GAPDH suggest a metabolic adaptation probably towards the use of 
other energetic substrates instead of glucose. In these way, search for other energetic 
metabolites and measurement of aminotransferases activity should be performed in 
cultured skin fibroblasts from MADD patients. In addition, analysis of cultured cells from 
other tissues such as muscle and liver may be of interest since these organs are the mainly 
affected in FAOD disorders (102,112,117). Indeed, this medium with glucose and no lipids 
is not the best option to test ETFDH deficiency. However, in a medium rich in fatty acids 
the proliferation of fibroblasts is impaired. 
Significant reduced activity of ATP synthase was noticed for all patients with the 
exception of MADD2. The protein levels of ATP synthase α subunit (ATPase α) 
corroborated the enzymatic measurement, although without statistical significance. This 
down-regulation was consistent with previous results reported in the literature (48,111), 
thus suggesting that OXPHOS integrity is impaired with, consequently, reduced levels of 
produced ATP. No differences were noticed for the ratio between GAPDH and ATPase α 
in MADD patient, except for MADD3 who presented significant reduced values. In fact, 
the down-regulation of OXPHOS may be an initiator of the Warburg effect, which 
represents a shifting from OXPHOS to glycolysis for energy and biosynthetic 
intermediates production (125). Our results suggest a metabolic adaptation to compensate 
ATP deficiency at the mitochondria similar to those previous described but without 
increased levels of GADPH (8). 
 
Regarding apoptosis, we found different protein expression patterns among MADD 
patients and controls (Figure 10). Significantly lower levels of the pro-apoptotic bcl-2 
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associated X protein (Bax) were noticed only for MADD4 patient. Similarly, no 
differences were found for the anti-apoptotic bcl-2 related protein A1 (Bcl-2A1) in MADD 
patients. Consequently, no significant differences of the ratio between Bax and Bcl-2A1 
were noticed for mild MADD patients, although this ratio was significantly lower in severe 
MADD patients. In general, we can conclude that these results suggest that the intrinsic 
apoptotic pathway is not being activated or is down-regulated in MADD disease. This is 
not consistent with previous findings from our group (48) and other groups (67,112), 
which have reported overexpression of pro-apoptotic proteins including Smac/diablo, 
anexin and girdin. Curiously, MADD4 patient showed significantly higher levels of 
cleaved caspase-3 (Casp-3). This result clearly suggest an up-regulation of apoptosis, being 
in accordance with the results reported in the literature (48). Casp-3 may be activated by 
other caspases besides the intrinsic apoptotic activation (126,127). In fact, several studies 
have reported an activation of caspase-12 (Casp-12) that leads to activation of Casp-3 in 
response of endoplasmic reticulum (ER) stress-induced (127,128). However, it was also 
reported an interplay of bcl-2 family proteins such as Bax and Bak in the activation of 
Casp-12 and that this protein is expressed in small amounts in humans (129). These 
findings make us hypothesize that mitochondria-ER interactions may be modulated in 
MADD pathogenesis and thus ER dynamics studies should also be performed. In addition, 
the activity of Casp-3 as other caspases (Casp-8, Casp-9 and Casp-12) should be measured 
in order to better understand the contribution of apoptotic pathways to MADD 
pathogenesis. Furthermore, since autophagy proteins are also targets of executioner 
caspases including Casp-3 (130), the integrated study of both autophagic and apoptotic 
proteins may contribute to better elucidate the mitochondrial dysfunctionality associated 
with MADD. 
 
In overall our study provides a global perspective of the mitochondrial dynamics in the two 
forms of MADD, mild and severe. Both forms presented down-regulation of mitochondrial 
biogenesis and metabolic adaptation. However, for the other biological processes assessed 
we did not find a pattern for the expressed proteins in MADD patients. Indeed, the 
different results obtained for the mechanisms studied may explain, at least in part, the 
variety of phenotypes observed in MADD patients. Despite the reduced number of patients 
due to the rarity of this disease, we can conclude that there is no straight full correlation 
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between disease severity and mitochondrial adaptations. Figure 11 represents an integrated 
perspective of the molecular mechanisms modulated by ETFDH deficiency in MADD 
patients. 
 
 
 
Figure 11. Integrated perspective of molecular mechanisms modulated by ETFDH deficiency in mild (A) 
and severe (B) forms of MADD. The proteins analyzed in the present study are highlighted with the up-
regulated presented in red and the down-regulated in green. Proteins with no expression variation are 
presented in blue and proteins differently expressed between patients are presented in orange. These proteins 
belong to different pathways that relate to mitochondria and many of them are specifically expressed on 
mitochondrion and thus these results for the different patients may explain why MADD is such a 
heterogeneous disorder. Figure made with Servier Medical Art. Abbreviations: ATG5: autophagy protein 5, 
Bax: bcl-2 associated X protein, Bcl-2A1: bcl-2 related protein A1, Casp-3: cleaved caspase-3, CS: citrate 
synthase, C-V: ATP synthase, ETFDH: electron transfer flavoprotein dehydrogenase, GAPDH: 
glyceraldehyde-3-phosphate dehydrogenase, MnSOD: manganese superoxide dismutase, mtTFA: 
mitochondrial transcription factor A, PGC-1α: peroxisome proliferator-activated receptor γ coactivator 1 
alpha, SIRT3: sirtuin 3, ROS: reactive oxygen species. 
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The integrated analysis of data obtained from the analyzes of cultured fibroblasts from 
both mild and severe MADD patients, allowed us to conclude that there is no straight full 
correlation between disease severity and mitochondrial adaptations. Indeed, both forms of 
the disease presented down-regulation of mitochondrial biogenesis and metabolic 
adaptation highlighted by lower levels of PGC-1α and GAPDH, respectively, in all MADD 
patients. For other biological processes assessed we did not find a clear relation between 
the expressed proteins and MADD phenotype. Expression levels of SIRT3 and activity of 
ATP synthase were found decreased in almost all patients, suggesting a mitochondrial 
dysfunction due to down-regulation of SIRT3-mitochondrial targets and ATP production. 
Down-regulation of SIRT3 was corroborated by decreased levels of PGC-1α. The 
expression levels of the other proteins analyzed were more diverse among MADD patients. 
The divergent results obtained for the several pathways related to mitochondrial dynamics 
may explain, at least in part, the heterogeneous phenotypes associated with MADD 
pathogenesis. 
 
MADD as other FAOD is a rare disorder of metabolism with high mortality rates. In this 
way, more studies are needed to better understand the genotype-phenotype correlation, 
involving other tissues that preferentially use FAO as energy source. For example, knock-
down of ETFDH in cardiomyocytes or hepatocytes may be performed. Cell viability assays 
are also of high importance since they may justify such differences in patients with the 
same mutation. The analysis of the contribution of other energetic metabolites such as 
amino acids and pyruvate would be interestingly to better comprehend the metabolic 
adaptation related to ETFDH deficiency. In parallel, the study of other apoptotic proteins 
as well as other mitophagy and fusion/fission markers will certainly help to better 
understand the differences among the MADD patients. Similarly, the study of other stress-
induced organelles including endoplasmic reticulum and its interplay with mitochondria 
would also contribute to explain the mitochondrial dysfunction. 
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Figure 12. Effect of ETFDH deficiency on mitochondrial density in cultured skin fibroblasts from MADD 
patients. Negative control (NC) for control, mild and severe skin fibroblasts were obtained from incubation 
with blocking solution instead of primary antibody (rabbit polyclonal anti-COX IV). Representative image of 
the merge between COX IV (red, Alexa Fluor® 594) and the cell nuclei (blue, Hoechst 33258) for NC. The 
absence of red (COX IV) dots compared to the merge where the primary antibody was added (Figure 9), 
indicates that there is specificity for the primary antibody chosen. All images were obtained with a 100x 
magnification in an Olympus IX-81 inverted epifluorescence microscope. The scale bar of images is 20 μm. 
